ReDiscover-2, a phase III study of zovegalisib (RLY-2608) + fulvestrant versus capivasertib + fulvestrant as treatment for locally advanced or metastatic *PIK3CA*-mutant HR+/HER2- breast cancer following recurrence or progression on or after treatment with a CDK4/6 inhibitor (trial in progress)

Hope S. Rugo,[1] Cristina Saura,[2] Komal Jhaveri,[3] Carlos Barrios,[4] Sherene Loi,[5] Frederik Marmé,[6] François-Clément Bidard,[7] Yeon Hee Park,[8] Peter Schmid,[9] Sarah L. Sammons,[10] Giuseppe Curigliano[11]


[1]City of Hope Comprehensive Cancer Center, Duarte, California, USA; [2]Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; [3]Memorial Sloan Kettering Cancer Center, New York, New York, USA; [4]Hospital São Lucas, PUCRS, Porto Alegre, Brazil; [5]Peter MacCallum Cancer Centre, Melbourne, Australia; [6]University Hospital Mannheim, Mannheim, Germany; [7]Institut Curie & VSVQ/Université Paris-Saclay, Institut Curie, Paris, France; [8]Samsung Medical Center, Seoul, South Korea; [9]Barts Cancer Institute, London, United Kingdom; [10]Dana-Farber Cancer Institute, Boston, Massachusetts, USA; [11]Istituto Europeo di Oncologia, IRCCS, University of Milano, Milano, Italy

Abstract #852
Poster board PS5-08-25

BACKGROUND

- Oncogenic *PIK3CA* mutations constitutively activate PI3Kα and drive approximately 40% of HR+/HER2- BC[1-3]
- Approved therapies for patients with *PIK3CA*-mutated HR+/HER2- ABC are non-mutant-selective PI3K pathway inhibitors, which have shown modest efficacy in combination with ET post-CDK4/6 inhibitor treatment (mPFS of ~5.5-8 months) and are limited by toxicities associated with broad inhibition of the PI3K pathway (hyperglycemia, rash, diarrhea, and stomatitis)[4-10]
- Zovegalisib (RLY-2608) is the first pan-mutant-selective inhibitor designed to overcome these limitations by selectively targeting mutated forms of PI3Kα while sparing wild type
- Zovegalisib binds a novel allosteric pocket of PI3Kα, distinct from approved inhibitors that bind the active orthosteric site, and emerging inhibitors that specifically target only the H1047R hotspot mutation (**Figure 1**)[11]


Figure 1: Zovegalisib Is the First Pan-Mutant-Selective PI3Kα Inhibitor



RATIONALE AND STUDY DESIGN


- The first-in-human ReDiscover study of zovegalisib demonstrated encouraging antitumor activity across a range of *PIK3CA* genotypes and a favorable safety profile when given in combination with fulvestrant in patients with *PIK3CA*-mutated HR+/HER2- ABC previously treated with a CDK4/6i[12]
  - 64 patients were dosed at the RP2D of 600 mg zovegalisib BID + fulvestrant
  - mPFS was 10.3 months (95% CI: 7.2-18.4) in the efficacy-evaluable population, excluding *PTEN/AKT* co-alterations (N=52)
  - In patients with measurable disease (N=31), ORR was 38.7% (95% CI: 21.8-57.8) and tumor reduction was observed in 80.6% of patients (**Figure 2**)
  - In the overall safety population (N=64), zovegalisib had a favorable safety profile consistent with wild-type sparing, mutant-selective PI3Kα inhibition and AEs were mostly low grade, reversible events (**Figure 3**)
- Based on these findings, zovegalisib in combination with fulvestrant is being studied in patients with *PIK3CA*-mutated HR+/HER2- ABC following recurrence or progression on or after a CDK4/6 inhibitor in this Phase III ReDiscover-2 study (NCT06982521)

Figure 2: Radiographic Tumor Reduction and Response per RECIST v1.1 (N=31)



Not shown: CR in patient with non-measurable disease.
Data as of 26 March 2025.

Figure 3. Zovegalisib Has a Favorable Safety Profile Consistent With Mutant-Selective PI3Kα Inhibition (N=64)



Data as of 26 March 2025.

STUDY DESIGN AND OBJECTIVES

Figure 4. ReDiscover-2 (RLY-2608-102): Phase III Registrational Trial for Post-CDK4/6 Inhibitor HR+/HER2- Advanced Breast Cancer With a *PIK3CA* Mutation (NCT06982521)[13]

Inclusion Criteria

- *PIK3CA*-mutated HR+/HER2- ABC
- No concomitant *PTEN* or *AKT* tumor alterations
- Measurable disease or evaluable bone-only disease
- Progression in ABC or adjuvant[a] setting on or after:
  - 1-2 lines ET, and
  - 1 line CDK4/6i

Exclusion Criteria

- Prior PI3Ki, AKTi, mTORi, ADC, IO, or investigational CDKi, CDK2i, CDK4i
- Progression on ≤6 mo of ET-based regimen for ABC
- Type 1 diabetes, or type 2 diabetes requiring antihyperglycemic medication
- Fasting plasma glucose ≥140 mg/dL, or HbA1c ≥7.0% (≥53 mmol/mol)

R 1:1 N=540

- Zovegalisib (400 mg BID[b]) + fulvestrant
- Capivasertib (400 mg BID[c] 4 days on, 3 days off) + fulvestrant

Stratification:
- *PIK3CA* mutation type
- Visceral disease
- Geography

- Primary endpoint: PFS (kinase, overall population)
- Key secondary endpoint: OS (kinase, overall population)
- Additional secondary endpoints: ORR, DoR, CBR, QoL

[a] Disease progression during or within 12 mo of completing adjuvant therapy.
[b] Zovegalisib administered with food.
[c] Capivasertib administered with or without food.

ReDiscover-2 is a global, multicenter, open-label, randomized Phase III study comparing the efficacy and safety of zovegalisib + fulvestrant to capivasertib + fulvestrant in adult patients with HR+/HER2- locally advanced or metastatic BC with *PIK3CA* mutation (**Figure 4**)

- Primary objective is to compare the efficacy of zovegalisib + fulvestrant relative to capivasertib + fulvestrant by assessment of PFS within the kinase domain mutation and overall populations by BICR
- Key secondary objective is to compare the efficacy of zovegalisib + fulvestrant relative to capivasertib + fulvestrant by assessment of OS within the kinase domain mutation and overall population
- Additional secondary endpoints include safety and tolerability, ORR, DoR, CBR, and QoL


ASSESSMENTS

- Tumor response is assessed in accordance with RECIST v1.1
- The primary endpoint of PFS is assessed by BICR
- Study visits for assessments of safety (including adverse events, vital signs, laboratory tests, and electrocardiograms), pharmacokinetics, and circulating tumor DNA are conducted periodically throughout study treatment

REDISCOVER-2 (RLY-2608-102) STATUS

- This pivotal, registrational Phase III clinical trial plans to open in >250 study centers globally
- Study enrollment began in July 2025 and recruitment is currently ongoing (**Figure 5**)

Figure 5. ReDiscover-2 Sites



Sites currently open or planned for Asia-Pacific, Europe, North America, and South America

References

1. Vasan N and Cantley LC. *Nat Rev Clin Oncol.* 2022;19(7):471-485.
2. Millis SZ, et al. *JAMA Oncol.* 2016;2(12):1565-1573.
3. Cancer Genome Atlas Network. *Nature.* 2012;490(7418):61-70.
4. Itovebi [Prescribing information]. Genentech, Inc.; 2025.
5. Truqap [Prescribing information]. AstraZeneca Pharmaceuticals LP; 2025.
6. Piqray [Prescribing information]. Novartis Pharmaceuticals Corporation; 2024.
7. Rugo HS, et al. *Ann Oncol.* 2020;31(8):1001-1010.
8. Turner NC, et al. *N Engl J Med.* 2023;388(22):2058-2070.
9. Chia S, et al. *J Clin Oncol.* 2023;41(suppl 16):TPS1078.
10. Juric D, et al. *Cancer Res.* 2022;82(suppl 4):PS-17-05.
11. Varkaris A, et al. *Cancer Discov.* 2024;14(2):240-257.
12. Sammons SL, et al. Presented at ASCO 2025; Poster 65.
13. https://www.clinicaltrials.gov/study/NCT06982521

Abbreviations

2L, second-line; ABC, advanced breast cancer; ADC, antibody-drug conjugate; AE, adverse event; AKT, protein kinase B; BC, breast cancer; BICR, blinded independent central review; BID, twice daily; CBR, clinical benefit rate; CDK, cyclin-dependent kinase; DoR, duration of response; ECOG, Eastern Cooperative Oncology Group; ET, endocrine therapy; HbA1c, glycosylated hemoglobin; HER2-, human epidermal growth factor receptor 2-negative; HR+, hormone receptor positive; I, inhibitor; IO, immuno-oncology therapy; mo, months; mTOR, mammalian target of rapamycin; NR, not reached; ORR, objective response rate; OS, overall survival; (m)PFS, (median) progression-free survival; PI3Kα, phosphatidylinositol 3-kinase alpha; PIK3CA, phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha; PTEN, phosphatase and tensin homolog; QoL, quality of life; R, randomization; RECIST v1.1, Response Evaluation Criteria in Solid Tumors version 1.1; TRAE, treatment-related adverse event.

Acknowledgments

The authors would like to thank the study participants and their families, and study investigators and research staff at the REDiscover-2 study sites. This study is sponsored by Relay Therapeutics, Inc. Medical writing support was provided by Yeeko Hiyama of BioConnections, LLC, funded by Relay Therapeutics.

Copies of this poster obtained through Quick Response (QR) Code are for personal use only and may not be reproduced without permission from SABCS® and the author of this poster.

For more information, please contact: ClinicalTrials@relaytx.com

Presented at the 2025 San Antonio Breast Cancer Symposium, December 9-12, 2025, San Antonio, TX